Targeted drug access for adults with advanced cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18) with advanced cancer that is not responding to standard treatment, or there is no standard option for you.
- Your general health is good enough for study treatment (ECOG performance status 0–2).
- Recent blood and organ tests must be within allowed limits (for example, white blood cells, hemoglobin, platelets, liver and kidney tests).
- You must have at least one measurable or evaluable cancer spot on scans or exam.
- Your tumor must have a recent molecular (genetic/biomarker) test showing a change that could be matched to a study targeted drug.
- You must provide a fresh tumor sample (biopsy) from the last 6 months or a liquid biopsy for additional testing before starting treatment.
- You must be able to sign consent and follow the study plan; if the drug is taken by mouth, you must be able to swallow and absorb it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.
This Phase 1 study tests early (first-in-program) cancer medicines in people whose cancer has not been adequately controlled. It helps researchers learn the safest dose and early signs of whether the treatment may work for different tumor types and treatments.
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.